Literature DB >> 21677824

Helicobacter pylori neutrophil activating protein as target for new drugs against H. pylori inflammation.

Theodora Choli-Papadopoulou, Filippos Kottakis, Georgios Papadopoulos, Stefanos Pendas.   

Abstract

Helicobacter pylori (H. pylori) infection is among the most common human infections and the major risk factor for peptic ulcer disease and gastric cancer. Within this work we present the implication of C-terminal region of H. pylori neutrophil activating protein in the stimulation of neutrophil activation as well as the evidence that the C-terminal region of H. pylori activating protein is indispensable for neutrophil adhesion to endothelial cells, a step necessary to H. pylori inflammation. In addition we show that arabino galactan proteins derived from chios mastic gum, the natural resin of the plant Pistacia lentiscus var. Chia inhibit neutrophil activation in vitro.

Entities:  

Keywords:  Gastric cancer; Helicobacter pylori; Helicobacter pylori neutrophil activating protein; Peptic ulcer disease

Mesh:

Substances:

Year:  2011        PMID: 21677824      PMCID: PMC3110918          DOI: 10.3748/wjg.v17.i21.2585

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  51 in total

1.  Neutrophil-activating protein (HP-NAP) versus ferritin (Pfr): comparison of synthesis in Helicobacter pylori.

Authors:  W G Dundon; A Polenghi; G Del Guidice; R Rappuoli; C Montecucco
Journal:  FEMS Microbiol Lett       Date:  2001-05-15       Impact factor: 2.742

2.  Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells.

Authors:  P Montemurro; G Barbuti; W G Dundon; G Del Giudice; R Rappuoli; M Colucci; P De Rinaldis; C Montecucco; N Semeraro; E Papini
Journal:  J Infect Dis       Date:  2001-02-23       Impact factor: 5.226

3.  Helicobacter pylori reinfection in Brazilian patients with peptic ulcer disease: a 5-year follow-up.

Authors:  Fernando M Silva; Tomas Navarro-Rodriguez; Ricardo C Barbuti; Rejane Mattar; Claudio L Hashimoto; Jaime N Eisig
Journal:  Helicobacter       Date:  2010-02       Impact factor: 5.753

4.  Oxidative-stress resistance mutants of Helicobacter pylori.

Authors:  Adriana A Olczak; Jonathan W Olson; Robert J Maier
Journal:  J Bacteriol       Date:  2002-06       Impact factor: 3.490

5.  The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses.

Authors:  Amedeo Amedei; Andrea Cappon; Gaia Codolo; Anna Cabrelle; Alessandra Polenghi; Marisa Benagiano; Elisabetta Tasca; Annalisa Azzurri; Mario Milco D'Elios; Gianfranco Del Prete; Marina de Bernard
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

6.  A primary Helicobacter pylori infection does not protect against reinfection in children after eradication therapy.

Authors:  Yelda A Leal; Alejandro Gómez; Armando Madrazo-de la Garza; Irma Ramos; Onofre Muñoz; Javier Torres
Journal:  Rev Invest Clin       Date:  2008 Nov-Dec       Impact factor: 1.451

7.  Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.

Authors:  Peter Malfertheiner; Viola Schultze; Bernd Rosenkranz; Stefan H E Kaufmann; Timo Ulrichs; Deborah Novicki; Francesco Norelli; Mario Contorni; Samuele Peppoloni; Duccio Berti; Daniela Tornese; Jitendra Ganju; Emanuela Palla; Rino Rappuoli; Bruce F Scharschmidt; Giuseppe Del Giudice
Journal:  Gastroenterology       Date:  2008-05-28       Impact factor: 22.682

8.  Identification of four new prokaryotic bacterioferritins, from Helicobacter pylori, Anabaena variabilis, Bacillus subtilis and Treponema pallidum, by analysis of gene sequences.

Authors:  D J Evans; D G Evans; H C Lampert; H Nakano
Journal:  Gene       Date:  1995-02-03       Impact factor: 3.688

9.  Mechanisms involved in Helicobacter pylori-induced inflammation.

Authors:  N Yoshida; D N Granger; D J Evans; D G Evans; D Y Graham; D C Anderson; R E Wolf; P R Kvietys
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

10.  Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study.

Authors:  Khansa Ben Mansour; Christophe Burucoa; Meriem Zribi; Afef Masmoudi; Sami Karoui; Lamia Kallel; Soufiène Chouaib; Samira Matri; Monia Fekih; Sonia Zarrouk; Mounir Labbene; Jalel Boubaker; Imed Cheikh; Mongi Ben Hriz; Nadia Siala; Abdelkarim Ayadi; Azza Filali; Nabil Ben Mami; Taoufik Najjar; Ahmed Maherzi; Mohamed Tahar Sfar; Chedlia Fendri
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-08-13       Impact factor: 3.944

View more
  9 in total

1.  Complete genome sequence of Helicobacter cinaedi strain PAGU611, isolated in a case of human bacteremia.

Authors:  Takatsugu Goto; Yoshitoshi Ogura; Hideki Hirakawa; Junko Tomida; Yuji Morita; Takaaki Akaike; Tetsuya Hayashi; Yoshiaki Kawamura
Journal:  J Bacteriol       Date:  2012-07       Impact factor: 3.490

Review 2.  Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.

Authors:  Haider Rahman; Marina Kim; Galen Leung; Jesse A Green; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

3.  Potential implications of Helicobacter pylori-related neutrophil-activating protein.

Authors:  Jannis Kountouras; Christos Zavos; Georgia Deretzi; Emmanuel Gavalas; Dimitrios Chatzopoulos; Panagiotis Katsinelos; Elena Tsiaousi; Stergios Gagalis; Stergios A Polyzos; Ioannis Venizelos
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

Review 4.  Non-pharmacological treatment of Helicobacter pylori.

Authors:  Haim Shmuely; Noam Domniz; Jacob Yahav
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

Review 5.  Helicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications.

Authors:  Hua-Wen Fu
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

6.  A First-in-Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers.

Authors:  Zadik Hazan; Konstantin Adamsky; Andre Lucassen; Leonard A Levin
Journal:  Clin Pharmacol Drug Dev       Date:  2019-06-28

7.  One-step chromatographic purification of Helicobacter pylori neutrophil-activating protein expressed in Bacillus subtilis.

Authors:  Kuo-Shun Shih; Chih-Chang Lin; Hsiao-Fang Hung; Yu-Chi Yang; Chung-An Wang; Kee-Ching Jeng; Hua-Wen Fu
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

8.  Serum Helicobacter pylori NapA antibody as a potential biomarker for gastric cancer.

Authors:  Jingjing Liu; Huimin Liu; Tingting Zhang; Xiyun Ren; Christina Nadolny; Xiaoqun Dong; Lina Huang; Kexin Yuan; Wenjing Tian; Yunhe Jia
Journal:  Sci Rep       Date:  2014-02-20       Impact factor: 4.379

9.  An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.

Authors:  Mohanraj Ramachandran; Di Yu; Alkwin Wanders; Magnus Essand; Fredrik Eriksson
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.